| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eterna Therapeutics Inc. | Sr. VP of Finance | Common Stock | 1.19K | $2.3K | $1.94 | Jun 21, 2024 | Direct |
| Eterna Therapeutics Inc. | Sr. VP of Finance | Restricted Stock Units | 437 | $1.08K | $2.48 | Jun 21, 2024 | Direct |
| Eterna Therapeutics Inc. | Sr. VP of Finance | Stock Option (Right to buy) | 80K | Apr 26, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ERNA | Eterna Therapeutics Inc. | Jun 21, 2024 | 3 | -$349 | 4 | Jun 25, 2024 | Sr. VP of Finance |
| ERNA | Eterna Therapeutics Inc. | Apr 26, 2024 | 1 | $0 | 4 | Apr 29, 2024 | Sr. VP of Finance |
| ERNA | Eterna Therapeutics Inc. | Jun 21, 2023 | 3 | -$444 | 4 | Jun 23, 2023 | Vice President of Finance |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | Jun 21, 2022 | 3 | -$1.71K | 4 | Jun 23, 2022 | Vice President of Finance |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | Mar 11, 2022 | 1 | $0 | 4/A | Mar 17, 2022 | Vice President of Finance |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | Jun 21, 2021 | 1 | $0 | 4 | Jun 22, 2021 | Vice President of Finance |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | Jun 21, 2021 | 0 | $0 | 3 | Jun 22, 2021 | Vice President of Finance |